Rezivertinib

DB21471InvestigationalSmall molecule

Rezivertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Rezivertinib is a epidermal growth factor receptor (EGFR) inhibitor. Rezivertinib is under... Rezivertinib is under investigation in clinical trial NCT06955325 (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations).

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₇H₃₀N₆O₃ · 486.576 g/mol (avg)
Code names: BPI-7711

Resolves to

Compound

UNIIU65F5M6BD5CAS1835667-12-3ChEMBLCHEMBL5314952ChEBI759643PubChem118912975

Clinical / RWD

PharmGKBPA166301721

Structure

InChIKeyBPMZUKYFIDPLEA-UHFFFAOYSA-NSMILESCOC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=CC=CC=C23)C=C(NC(=O)C=C)C(OCCN(C)C)=C1

Targets

P00533EGFR

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rezivertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account